Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1230126 | 1.00 | ALDH1A1 (0.30) | — | |
| Hydrochloric Acid SCHEMBL31256107 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL438557 | 1.00 | ALDH1A1 (0.30) | — | |
| Hydrochloric Acid SCHEMBL31155774 | 0.94 | — | — | |
| SCHEMBL29511758 | 0.94 | — | — | |
| SCHEMBL3356662 | 0.94 | TSHR (0.33) | — | |
| SCHEMBL30577237 | 0.94 | TSHR (0.33) | — | |
| SCHEMBL6756409 | 0.94 | TSHR (0.33) | — | |
| SCHEMBL7085 | 0.94 | TSHR (0.33) | — | |
| SCHEMBL379510 | 0.94 | TSHR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028308-A1 | METHODS FOR MAKING AND USING ENDOXIFEN | ATOSSA THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | claimed |
| CN-119630640-A | Process for the production of O-substituted serine derivatives | 中外制药株式会社 | 2025-03-14 | — | — | CN | claimed |
| CN-111328280-A | Methods of making and using endoxifen | 阿托萨治疗学公司 | 2020-06-23 | — | — | CN | claimed |
| EP-2276753-A1 | INTERMEDIATES FOR THE PREPARATION OF (3R, 4S) -1- (4-FLUOROPHENYL) -3- [ (3S) -3- (4-FLUOROPHENYL) -3-HYDROXYPROPYL) ] -4- (4-HYDROXYPHENYL) -2-AZETIDINONE | Zentiva, K.S. (CZ) | 2011-01-26 | — | — | EP | claimed |
| WO-2009106021-A1 | INTERMEDIATES FOR THE PREPARATION OF (3R, 4S) -1- (4-FLUOROPHENYL) -3- [ (3S) -3- (4-FLUOROPHENYL) -3-HYDROXYPROPYL) ] -4- (4-HYDROXYPHENYL) -2-AZETIDINONE | ZENTIVA, K.S. (CZ) | 2009-09-03 | — | — | WO | claimed |
| WO-2009067960-A2 | A METHOD OF MANUFACTURING (3R,4S)-L-(4-FLUOROPHENYL)-3-[(3S)-3-(4-FLUOROPHENYL)-3- HYDROXYPROPYL)]-4-(4-HYDROXYPHENYL)-2-AZETIDINONE AND ITS INTERMEDIATES | ZENTIVA, A.S. (CZ) | 2009-06-04 | — | — | WO | claimed |
| EP-4746863-A1 | ENDOXIFEN COMPOSITIONS AND METHODS OF USE THEREOF AND SYNTHESIS THEREOF | Atossa Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260028308-A1 | METHODS FOR MAKING AND USING ENDOXIFEN | ATOSSA THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12479790-B2 | Methods for making and using endoxifen | ATOSSA THERAPEUTICS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250282710-A1 | METHODS FOR MAKING AND USING ENDOXIFEN | ATOSSA THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250223256-A1 | METHODS FOR MAKING AND USING ENDOXIFEN | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-12281056-B2 | Methods for making and using endoxifen | ATOSSA THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-12275684-B2 | Methods for making and using endoxifen | ATOSSA THERAPEUTICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| EP-0789022-B1 | Difluoroprostacyclins, intermediates for production thereof and processes for production thereof | ASAHI GLASS CO LTD (JP) | 2003-06-18 | — | — | EP | disclosed |
| EP-0669329-B1 | Difluorprostacyclins, intermediates for production thereof and processes for production thereof | ASAHI GLASS CO LTD (JP) | 1998-05-20 | — | — | EP | disclosed |
| US-5747531-A | STABILITY; ANTICOAGULANTS, VASODILATORS | ASAHI GLASS COMPANY LTD. (JP) | 1998-05-05 | — | — | US | disclosed |
| US-5616732-A | Intermediates for difluoroprostacyclins and methods for their production | ASAHI GLASS COMPANY LTD. (JP) | 1997-04-01 | — | — | US | disclosed |
| US-5538995-A | Difluoroprostacyclins | ASAHI GLASS COMPANY LTD. (JP) | 1996-07-23 | — | — | US | disclosed |
| EP-0669329-A1 | Difluorprostacyclins, intermediates for production thereof and processes for production thereof | ASAHI GLASS COMPANY LTD. (JP) | 1995-08-30 | — | — | EP | disclosed |
| US-4304925-A | ESTERIFYING IN THE PRESENCE OF AN ORGANOMETALLIC CATALYST | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1981-12-08 | — | — | US | disclosed |